Vivanta Industries Limited has published its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The disclosure, made on July 30, 2026, includes the financial statements alongside a limited review report, providing investors with an early view of the company’s performance in Q1FY27. This release ensures timely transparency for shareholders ahead of formal statutory filings, allowing market participants to assess the firm’s operational health during the initial quarter of the new fiscal year.

The unaudited results were reviewed by the Audit Committee and subsequently approved by the Board of Directors during meetings held in July 2026. In compliance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Vivanta Industries Limited issued an intimation to the Bombay Stock Exchange (BSE) regarding the publication of these results. The full format of the financial results is available on the BSE website and the company’s official portal.

Regulatory Disclosures and Shareholder Updates

Alongside the financial results, the company published notices in The Indian Express (English) and Financial Express (Gujarati), as required by listing norms. The publication serves as a public record of the unaudited standalone and consolidated figures. The intimation was signed by Hemant Amrish Parikh, Managing Director, affirming the accuracy of the disclosures submitted to the Department of Corporate Services at BSE Limited.

Physical Share Transfer Window

Vivanta Industries Limited also highlighted a critical regulatory update for shareholders holding physical shares. Pursuant to SEBI Circular No. HO/38/13/11(2) MISRD-POD-1/3750/2026 dated January 30, 2026, the window for accepting physical share transfer requests has been extended from February 5, 2026, to February 4, 2031. This extension applies specifically to claims filed before April 1, 2019, that were rejected or returned due to documentation or procedural deficiencies.

Shareholders must ensure their shares are transferred only in demat mode during this period. Applicants are required to hold a demat account and submit the Client Master List (CML) along with transfer documents. The Registrar and Transfer Agent (RTA), Purva Share Registry (India) Limited, can be contacted via email at support@purvashare.com or at their Mumbai office for document submission.

What the Numbers Show

While specific revenue or profit figures are not detailed in this intimation notice, the publication of the limited review report indicates that the company’s financial data has undergone independent verification by statutory auditors. This step is crucial for maintaining investor confidence, particularly for mid-cap entities where timely access to verified financial data reduces information asymmetry. The availability of the full results on the BSE and company websites allows analysts to dissect segment-wise performance and margin trends immediately upon release.

Shareholders holding physical shares are urged to update their KYC details and convert holdings to demat form to avoid complications. Additionally, unclaimed dividends must be claimed promptly; otherwise, they will be transferred to the Investor Education and Protection Fund (IEPF) after seven years, along with accrued interest. This proactive communication underscores the company’s focus on compliance and shareholder protection.

Vivanta Industries Limited reported a consolidated net profit of ₹97.82 lakh for the quarter ended June 30, 2026 (Q1FY26), compared to a net profit of ₹53.94 lakh in the corresponding quarter of FY25. The company’s revenue from operations stood at ₹8,022.22 lakh for the quarter, an increase from ₹7,588.50 lakh in Q1FY25. This marks a return to profitability from a loss of ₹80.37 lakh reported in the preceding quarter (Q4FY25). The Board of Directors approved the unaudited standalone and consolidated financial results during its meeting held on July 29, 2026, at the company’s registered office in Ahmedabad.

The meeting, originally scheduled for July 24, 2026, was postponed due to adverse weather conditions. In addition to approving the financial results, the Board took note of several governance matters, including the declaration of independence by independent directors under Section 149(7) of the Companies Act, 2013, and Regulation 25(8) of the SEBI Listing Regulations. The Board also noted the issuance of duplicate share certificates to Mr. Rajesh Bhanji Lakum under Regulation 39(3) of the SEBI Listing Regulations.

Key Financial Highlights

The company’s financial performance showed significant improvement in the first quarter of FY26. Consolidated total income reached ₹8,076.27 lakh, driven primarily by revenue from operations. Total expenses were recorded at ₹7,978.45 lakh. The profit before tax was ₹97.82 lakh, with no tax expense incurred for the quarter.

On a standalone basis, the company reported a net profit of ₹76.80 lakh for Q1FY26, compared to ₹32.89 lakh in Q1FY25. Standalone revenue from operations was ₹336.49 lakh, down significantly from ₹1,056.05 lakh in the same quarter last year, indicating that the majority of the group’s revenue is generated through its subsidiaries and joint ventures.

Strategic Developments

During the meeting, the Board took note of the execution of business collaboration agreements with Qness Pharmaceuticals, a proprietorship concern engaged in the manufacture, supply, branding, and marketing of pharmaceutical and allied products. This collaboration aligns with the company’s diversified activities in pharmaceuticals and healthcare. The Board also authorized designated signatories to open trading and demat accounts with Motilal Oswal Financial Services Limited (MOFSL).

What the Numbers Show

The sharp contrast between the standalone and consolidated results highlights Vivanta Industries’ reliance on its group entities for revenue generation. While standalone revenue declined by approximately 68% year-on-year, consolidated revenue grew by nearly 6%, suggesting robust performance in its subsidiary operations. The turnaround from a quarterly loss of ₹80.37 lakh in Q4FY25 to a profit of ₹97.82 lakh in Q1FY26 underscores improved operational efficiency or favorable mix shifts within the group. Investors should monitor whether this profitability trend sustains as the company expands its pharmaceutical partnerships.